mRNA Vaccines Pipeline by the Numbers (2026): 459 Clinical Trials

The global mRNA vaccine landscape is undergoing a dramatic structural transformation. Following the unprecedented surge in clinical development during the COVID-19 pandemic, the modality experienced a sharp contraction in trial initiations between 2022 and 2024. However, registry data from 2025 and 2026 reveals a partial recovery driven by non-COVID prophylactic vaccines—specifically seasonal influenza, respiratory syncytial virus (RSV), cytomegalovirus (CMV), and herpes simplex virus (HSV)—alongside individualized neoantigen cancer vaccines. As Moderna approaches an August 5, 2026 FDA PDUFA decision date for mFLUSIVA (mRNA-1010), the biopharma industry faces its first major test of whether mRNA technology can establish a commercially viable second pillar beyond SARS-CoV-2.

+-----------------------------------------------------------------------------------+
|                     GLOBAL mRNA VACCINE PIPELINE TRANSITION                        |
+-----------------------------------------------------------------------------------+
|                                                                                   |
|   COVID-19 ERA (2020–2023)            ──► SECOND-WAVE COMMERCIAL HORIZON (2026)     |
|   • Single-target focus (SARS-CoV-2)     • Non-COVID Prophylactic (Flu, RSV, CMV)|
|   • 277 total clinical trials            • 182 non-COVID trials (Flu 35, RSV 15)  |
|   • Emergency Use Authorization (EUA)    • Standard/Accelerated BLA Review        |
|                                          • mFLUSIVA PDUFA: August 5, 2026         |
|                                                                                   |
+-----------------------------------------------------------------------------------+

---

Direct Commercial & Regulatory Answer

How big is the global mRNA vaccine pipeline in 2026, how far has it expanded beyond COVID-19, and will Moderna's mFLUSIVA (mRNA-1010) establish seasonal influenza as a commercially viable second pillar? Analysis of ClinicalTrials.gov registry data (scanning 595,630 total clinical studies) reveals 459 clinical trials evaluating prophylactic and therapeutic mRNA vaccines. While COVID-19 trials represent 60.3% (277 trials) of the historical dataset, the active non-COVID pipeline has expanded to ~182 trials across seasonal influenza (35), RSV (15), HSV (14), CMV (8), HIV (6), other infectious pathogens (48), and individualized cancer vaccines (~50). Following a peak of 129 new trial starts in 2021, annual initiations plummeted to a trough of 38 in 2024 before rebounding to 45 in 2025 and 28 year-to-date in 2026. Moderna's mFLUSIVA (mRNA-1010)—backed by a unanimous 9-0 FDA VRBPAC vote on June 18, 2026 and an August 5, 2026 PDUFA goal date—serves as the critical test for platform diversification, demonstrating 26.6% relative efficacy over standard flu shots in Phase 3 trials and establishing a dual-track BLA approval pathway for adults 50–64 and adults $\ge 65$.

---

Registry Search Methodology & Dataset Scope

To isolate the mRNA vaccine trial cohort from broader nucleic acid therapeutics, our analysis applied a structured multi-parameter filter to ClinicalTrials.gov registry data (snapshot dated July 25, 2026):

1. Inclusion Keyword Criteria: Interventions matching broad terms (mRNA, messenger RNA, lipid nanoparticle vaccine, nucleoside-modified mRNA, self-amplifying mRNA, saRNA) combined with vaccine indication flags.
2. Exclusion Criteria: Studies evaluating short interfering RNA (siRNA, e.g., inclisiran, patisiran), antisense oligonucleotides (ASOs), gene editing mRNA vectors (CRISPR/Cas9 mRNA delivery), or non-vaccine oncology therapeutics were explicitly excluded to preserve modality isolation (RNA therapeutics clinical trials).
3. Data Verification & Deduplication: Duplicate clinical record entries, diagnostic-only imaging sub-studies, and discontinued pre-clinical filings were removed, leaving a clean global cohort of 459 clinical trials.

---

The Global mRNA Vaccine Landscape: 459 Clinical Trials Analyzed

To evaluate the true volume and distribution of mRNA vaccine development, we performed a comprehensive scan of the ClinicalTrials.gov database (595,630 total records examined), isolating all clinical studies evaluating lipid nanoparticle (LNP)-encapsulated or naked mRNA prophylactic and therapeutic vaccines.

                   mRNA VACCINE INDICATION DISTRIBUTION (459 TRIALS)
  ┌────────────────────────────────────────────────────────────┬───────────┐
  │ COVID-19 / SARS-CoV-2: 277 Trials (60.3%)                  │ Non-COVID │
  │ Therapeutic Cancer Vaccines: 50 Trials (10.9%)             │ (39.7%)   │
  │ Seasonal & Avian Influenza: 35 Trials (7.6%)               │           │
  │ RSV: 15 Trials (3.3%) | HSV: 14 Trials (3.1%)               ├───────────┤
  │ CMV: 8 Trials | HIV: 6 Trials | Other Infectious: 48 Trials  │ Cancer 50 │
  └────────────────────────────────────────────────────────────┴───────────┘

Comprehensive Indication Breakdown of the mRNA Vaccine Pipeline

Across the cohort, industry sponsors run 258 trials and non-industry (academic, government, and network) sponsors run the remaining 201; by phase the registry records 114 Phase 1, 77 Phase 2, and 55 Phase 3 trials.

The data highlights a clear bifurcation: while COVID-19 clinical trials account for 277 studies (60.3%), new COVID trial starts have slowed to a trickle. The growth edge of the mRNA platform resides in the ~182 non-COVID trials, where commercial sponsors are competing to establish non-egg-based manufacturing dominance in seasonal respiratory and latent viral infections.

---

The COVID Crash and Post-2024 Recovery Curve

Tracking trial initiations by start year reveals the dramatic boom-and-bust cycle of the initial mRNA investment wave and its subsequent stabilization.

                      ANNUAL mRNA VACCINE TRIAL STARTS (2018–2026)
  140 ┼───────────────────────────────── 129 (Peak) ──────────────────────────
  120 ┼                                   │
  100 ┼                                   │         91
   80 ┼                                   │          │         72
   60 ┼                                   │          │          │                    45
   40 ┼                         20        │          │          │         38          │        28 (YTD)
   20 ┼       7        7         │        │          │          │          │          │         │
    0 ┴───────┴────────┴─────────┴────────┴──────────┴──────────┴──────────┴──────────┴─────────┴──
            2018     2019      2020     2021       2022       2023       2024       2025      2026

Start Year Trajectory & Pipeline Evolution Dynamics

• Pre-Pandemic Baseline (2018–2019): Only 7 new mRNA vaccine trial starts were logged per year, primarily early-phase safety studies conducted by Moderna (CMV, Chikungunya) and BioNTech (personalized cancer vaccines).
• The Pandemic Surge (2020–2021): Trial initiations jumped to 20 in 2020 and exploded to an all-time peak of 129 new starts in 2021, as global clinical trial networks mobilized to evaluate monovalent, bivalent, and variant-specific SARS-CoV-2 candidates.
• The Post-Pandemic Contraction (2022–2024): As global population immunity rose and vaccine demand declined, trial starts fell steadily to 91 in 2022, 72 in 2023, and hit a trough of 38 in 2024—a 70.5% drop from the 2021 peak.
• The Second-Wave Recovery (2025–2026): Initiations rebounded to 45 in 2025 and 28 year-to-date in 2026. Crucially, the recovery is concentrated in non-COVID programs — seasonal flu, combination respiratory shots, and Phase 3 cancer vaccine trials — rather than a return of COVID demand (cell and gene therapy clinical trials).

This trajectory reflects a fundamental maturation of the biopharma investment cycle. During the height of the COVID-19 pandemic, capital poured indiscriminately into any mRNA construct targeting SARS-CoV-2. As emergency demand waned, biopharma leadership terminated low-probability COVID programs and redirected clinical resources toward high-unmet-need markets where conventional protein or egg-based vaccines exhibit known efficacy limitations.

---

Sponsor Concentration & Competitive Hierarchy

The commercial mRNA vaccine pipeline is highly concentrated among a small cadre of biopharma developers possessing proprietary lipid nanoparticle (LNP) delivery platforms and high-throughput mRNA synthesis infrastructure.

                      TOP COMMERCIAL MRNA VACCINE DEVELOPERS
  ┌────────────────────────────────────────────────────────────┬───────────┐
  │ ModernaTX, Inc.: 68 Trials (26.4% of Industry Total)       │ BioNTech  │
  │ BioNTech SE: 31 Trials (12.0%)                             │ (12.0%)   │
  │ Sanofi Pasteur: 16 Trials (6.2%)                           ├───────────┤
  │ GlaxoSmithKline (GSK): 13 Trials (5.0%)                    │ Sanofi 16 │
  │ AIM Vaccine: 13 Trials | Pfizer: 10 Trials | CureVac: 7    ├───────────┤
  │ Abogen: 7 | Gritstone: 6 | Arcturus: 6 | Others: 81        │ GSK 13    │
  └────────────────────────────────────────────────────────────┴───────────┘

Industry Sponsor Ranking by Pipeline Volume & Stage

Moderna alone accounts for 68 clinical trials (26.4% of all industry-sponsored mRNA studies), followed by BioNTech with 31 trials. Industry sponsors command 258 trials (56.2% of the total cohort), while academic, government (NIH, DARPA), and institutional networks account for the remaining 201 studies (ADC trials by the numbers).

---

Latent Virus & Complex Pathogen Pipeline Targets: RSV, CMV, HSV, and HIV

Beyond seasonal influenza, commercial developers are advancing mRNA constructs against complex viral pathogens that have historically defied traditional vaccine technologies due to structural antigen instability or immune evasion mechanisms.

1. Respiratory Syncytial Virus (mRESVIA / mRNA-1345): Approved by the FDA in May 2024 for adults aged 60 and older, mRESVIA encodes a prefusion-stabilized F glycoprotein. In the pivotal Phase 3 ConquerRSV trial ($N=35,500$), mRESVIA achieved 83.7% efficacy against lower respiratory tract disease (LRTD) with two or more symptoms, demonstrating that single-dose pre-filled syringe mRNA administration can compete directly with protein subunit vaccines (Arexvy and Abrysvo).
2. Cytomegalovirus (mRNA-1647): Cytomegalovirus (CMV) is the leading infectious cause of congenital birth defects. Moderna's mRNA-1647 is a hexavalent vaccine encoding five mRNAs that form the pentameric complex (gH/gL/UL128/UL130/UL131A) and one mRNA encoding glycoprotein B (gB). The pivotal Phase 3 CMVictory trial ($N=7,300$ seronegative women aged 16 to 40) is evaluating primary prevention of maternal CMV infection, addressing a multi-billion dollar commercial market with zero currently approved vaccines.
3. Herpes Simplex Virus (BNT163 & mRNA-1608): BioNTech's BNT163 targets HSV-2, encoding three viral glycoproteins (gD, gC, gE) to block entry and immune evasion. Moderna's mRNA-1608 targets HSV-2 mucosal viral shedding. Phase 1/2 clinical data demonstrates robust CD4+ and CD8+ T-cell responses capable of reducing recurrent genital lesions.
4. Human Immunodeficiency Virus (mRNA-1644 / IAVI): In collaboration with the International AIDS Vaccine Initiative (IAVI), Moderna is evaluating germline-targeting mRNA immunogens (eOD-GT8 60mer) designed to prime naive B cells to produce broadly neutralizing antibodies (bNAbs) against the CD4 binding site of HIV-1 envelope glycoprotein.

---

Manufacturing Economics & Lipid Nanoparticle (LNP) Production Scaling

The long-term commercial competitiveness of mRNA vaccines beyond emergency pandemic use depends heavily on manufacturing unit economics, enzymatic synthesis efficiency, and raw material supply chains.

                      IN VITRO TRANSCRIPTION & LNP ENCAPSULATION
  ┌──────────────────────────────────────────────────────────────────────────┐
  │ STEP 1: Linearized Plasmid DNA Template Generation                       │
  │ Escherichia coli fermentation ──► Restriction Enzyme Linearization       │
  ├──────────────────────────────────────────────────────────────────────────┤
  │ STEP 2: In Vitro Transcription (IVT) Reaction                            │
  │ T7 RNA Polymerase + NTPs + N1-methylpseudouridine (m1Psi) + Cap-1 Analog │
  ├──────────────────────────────────────────────────────────────────────────┤
  │ STEP 3: Microfluidic LNP Encapsulation                                   │
  │ Ethanol lipid phase (Ionizable lipid + DSPC + Cholesterol + PEG-lipid)   │
  │ mixed with aqueous mRNA buffer in impingement jet mixer                   │
  ├──────────────────────────────────────────────────────────────────────────┤
  │ STEP 4: Tangential Flow Filtration (TFF) & Sterile Fill-Finish           │
  │ Buffer exchange, ethanol removal, 0.22 micron filtration, vial filling    │
  └──────────────────────────────────────────────────────────────────────────┘

Manufacturing Unit Cost & Technology Trade-Offs

1. Cap-1 Analog Economics vs. Enzymatic Capping: Early mRNA manufacturing used Vaccinia Capping Enzyme (VCE) in a two-step post-transcriptional reaction. Modern commercial processes favor co-transcriptional Cap-1 analogs (such as CleanCap), which can push IVT capping efficiency upward of 95% and simplify the upstream process relative to enzymatic capping.
2. Ionizable Lipid Patent Landscape: The LNP encapsulation matrix consists of four functional lipids: an ionizable amino lipid (e.g., SM-102 in Moderna's platform, ALC-0315 in Pfizer/BioNTech's), a helper phospholipid (DSPC), cholesterol, and a PEGylated lipid (PEG2000-DMG). The proprietary ionizable lipid layer has been a heavily licensed, patent-constrained input across the industry.
3. Yield & Batch Scalability: Commercial IVT reactors typically yield on the order of grams of purified, N1-methylpseudouridine-modified mRNA per liter of reaction volume. The core advantage is that mRNA's cell-free, enzymatic synthesis avoids the long lead times of cell-line or egg-based expansion — the real driver of its strain-reformulation speed advantage rather than raw per-dose cost.

The speed advantage of mRNA manufacturing is particularly critical for seasonal influenza. Egg-based flu vaccine production requires selecting candidate vaccine viruses (CVVs) six to months ahead of the flu season, forcing WHO and FDA advisory panels to predict circulating strains early. mRNA technology allows strain selection to be delayed by up to two months, dramatically improving antigenic match against late-emerging viral mutations.

---

Therapeutic Individualized Cancer Vaccines (iNeST Platform)

Beyond prophylactic infectious disease vaccines, therapeutic individualized neoantigen specific therapy (iNeST) represents a major second commercial pillar for mRNA technology.

                      INDIVIDUALIZED CANCER VACCINE WORKFLOW (iNeST)
  ┌──────────────────────────────────────────────────────────────────────────┐
  │ STEP 1: Tumor & Healthy Tissue Sequencing                                │
  │ Next-Generation Sequencing (NGS) of patient tumor biopsy + blood sample   │
  ├──────────────────────────────────────────────────────────────────────────┤
  │ STEP 2: Bioinformatic Neoantigen Prediction & Ranking                    │
  │ Machine-learning algorithms identify up to 34 high-affinity MHC-I/II epitopes│
  ├──────────────────────────────────────────────────────────────────────────┤
  │ STEP 3: On-Demand mRNA Synthesis & LNP Formulation                       │
  │ Individualized poly-epitope mRNA construct synthesized within 4 to 6 weeks│
  ├──────────────────────────────────────────────────────────────────────────┤
  │ STEP 4: Combination Administration with Immune Checkpoint Blockade       │
  │ Co-administered with anti-PD-1 (Keytruda) to drive CD8+ T-cell expansion │
  └──────────────────────────────────────────────────────────────────────────┘

1. Moderna / Merck mRNA-4157 (V940): In the KEYNOTE-942 Phase 2b trial in resected high-risk stage III/IV melanoma, mRNA-4157 plus pembrolizumab (Keytruda) reduced the risk of recurrence or death by 44% compared to pembrolizumab monotherapy (hazard ratio $\approx 0.56$). Phase 3 programs in adjuvant melanoma and non-small cell lung cancer are now enrolling.
2. BioNTech / Roche BNT122 (Autogene Cevumeran): In Phase 1b clinical trials in resected pancreatic ductal adenocarcinoma (PDAC), autogene cevumeran induced neoantigen-specific T-cell expansion in 50% of treated patients, with T-cell responders showing a significantly longer recurrence-free survival (RFS) compared to non-responders. Phase 2 trials in adjuvant pancreatic cancer (NCT05968326) and high-risk colorectal cancer are currently ongoing.
3. Regulatory Designations & On-Demand Logistics: Both mRNA-4157 and BNT122 have received FDA Breakthrough Therapy Designation and EMA PRIME status. Commercialization requires building specialized, rapid-turnaround "vein-to-vein" automated manufacturing facilities capable of synthesizing patient-customized mRNA batches within 28 days of biopsy receipt.

---

Avian Influenza (H5N1) Pandemic Preparedness Pipeline

In addition to seasonal influenza, global public health agencies have prioritized mRNA technology for avian influenza (H5N1) pandemic preparedness.

1. Rapid Strain Matching: In response to expanding dairy cattle and poultry H5N1 outbreaks in North America, the US Biomedical Advanced Research and Development Authority (BARDA) awarded funding to Moderna and BioNTech to advance pre-pandemic H5N1 mRNA vaccine candidates into Phase 1/2 clinical testing.
2. Phase 1 H5N1 Clinical Signals: Moderna's mRNA-1018 pandemic candidate and BioNTech's H5N1 program have advanced into early-stage clinical testing, with the platform's faster strain-matching positioned as the core advantage over egg-based pandemic vaccines; detailed immunogenicity readouts are still maturing.
3. Warm-Base Manufacturing Reserve: US and EU preparedness efforts have explored "warm-base" agreements with mRNA producers so that facility capacity could be redirected quickly in a declared public health emergency, though the specific scale and timelines of such arrangements are not publicly fixed.

---

The Commercial Crucible: Moderna's mFLUSIVA (mRNA-1010)

The pivotal catalyst for the entire non-COVID mRNA platform is Moderna's mFLUSIVA (mRNA-1010), an investigational trivalent seasonal influenza vaccine targeting influenza A/H1N1, A/H3N2, and influenza B/Victoria (the B/Yamagata lineage is no longer in global circulation and has been dropped from current seasonal vaccine compositions).

                      mFLUSIVA (mRNA-1010) REGULATORY & CLINICAL SUMMARY
  ┌──────────────────────────────────────────────────────────────────────────┐
  │ FDA VRBPAC ADCOM VOTE (June 18, 2026)                                    │
  │ • Unanimous 9-0 vote: Benefit-risk profile is favorable for adults >=50 │
  ├──────────────────────────────────────────────────────────────────────────┤
  │ FDA PDUFA GOAL DATE: August 5, 2026                                      │
  │ • Standard BLA Approval track for adults 50–64 years                     │
  │ • Accelerated BLA Approval track for adults >=65 years (Confirmatory P305)│
  ├──────────────────────────────────────────────────────────────────────────┤
  │ PIVOTAL PHASE 3 EFFICACY (P304 Trial, NCT06602024, N > 40,000)           │
  │ • 26.6% relative vaccine efficacy vs standard-dose seasonal comparator  │
  │ • 47.9% relative efficacy against healthcare outcomes (ED/hospitalization)│
  │ • Superior immunogenicity GMTs vs Fluzone High-Dose in adults >=65      │
  └──────────────────────────────────────────────────────────────────────────┘

Clinical Evidence & Regulatory Pathway for mFLUSIVA

1. VRBPAC Unanimous Advisory Vote: On June 18, 2026, the FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted 9-0 that the efficacy and safety data support a favorable benefit-risk profile for mRNA-1010 in adults aged 50 and older.
2. Pivotal Phase 3 P304 Trial (NCT06602024): In a randomized, active-controlled Phase 3 trial enrolling over 40,000 adults aged 50 and older across northern and southern hemisphere seasons, mFLUSIVA demonstrated a 26.6% relative vaccine efficacy against RT-PCR-confirmed influenza-like illness compared to a licensed standard-dose seasonal flu comparator. Against severe healthcare outcomes (emergency department visits and hospitalizations), mFLUSIVA demonstrated a 47.9% relative efficacy reduction.
3. Two-Track Regulatory Basis: Moderna submitted a Biologics License Application (BLA) under a dual regulatory track: seeking standard approval for adults 50–64 years based on clinical efficacy, and accelerated approval for adults $\ge 65$ years based on superior hemagglutination inhibition (HAI) antibody titers relative to Fluzone High-Dose, backed by an ongoing postmarketing confirmatory trial (P305).

---

Next-Generation mRNA Horizons: Combination & Cancer Vaccines

Beyond monovalent flu shots, the future commercial value of mRNA technology lies in multi-pathogen combination vaccines and individualized cancer immunotherapies (bispecific antibody trials by numbers).

                       NEXT-GENERATION mRNA VACCINE FRONTIERS
  ┌─────────────────────────────────────────┬────────────────────────────────┐
  │ MULTI-PATHOGEN COMBINATIONS             │ INDIVIDUALIZED CANCER VACCINES │
  │ • mRNA-1083 (Moderna): Flu + COVID-19   │ • mRNA-4157 / V940 (Moderna):  │
  │   Phase 3 immunogenicity met            │   Neoantigen + Keytruda (Melanoma) │
  │ • mRESVIA (mRNA-1345): RSV Approved     │ • BNT122 (BioNTech/Genentech): │
  │ • mRNA-1647 (Moderna): Phase 3 CMV      │   Autogene Cevumeran (Pancreatic)  │
  └─────────────────────────────────────────┴────────────────────────────────┘

Key Late-Stage mRNA Assets Beyond Monovalent Respiratory Shots

Self-amplifying mRNA (sa-mRNA) technology, pioneered commercially by Arcturus Therapeutics and CSL Seqirus with Kostaive, represents a major sub-modality evolution. By encoding an alphavirus RNA-dependent RNA polymerase alongside the antigen sequence, sa-mRNA replicates inside host cells, delivering equivalent immunogenicity at one-tenth the lipid nanoparticle dose of conventional mRNA vaccines, significantly lowering reactogenicity and raw material manufacturing costs (anti-obesity phase 3 pipeline).

---

Detailed Pipeline Summary Table of Major mRNA Developers

To provide an executive overview of industry progress, we summarize the lead clinical programs across the six largest commercial developers.

Executive Pipeline Comparison Table

---

Commercial & Regulatory Execution Risks

Despite major technical progress, the non-COVID mRNA vaccine platform faces several commercial and regulatory head-winds:

1. Reactogenicity & Tolerability Profiles: In Phase 3 trials, mRNA vaccines generally induce higher rates of transient local injection-site pain, fatigue, and low-grade pyrexia than conventional split-virion or adjuvanted subunit flu vaccines (e.g., Fluzone High-Dose or Fluad). For elderly populations ($\ge 65$), commercial adoption depends on prescribers accepting mild reactogenicity in exchange for superior 26.6% relative efficacy.
2. Ultra-Cold Supply Chain Requirements: While second-generation mRNA formulations (including mFLUSIVA) are stable at standard refrigerator temperatures ($2^\circ\text{C}$ to $8^\circ\text{C}$) for up to 30 days, long-term storage still requires $-20^\circ\text{C}$ freezers, creating distribution friction in retail pharmacy channels compared to room-temperature stable protein vaccines.
3. Payer Contracting & Multi-Valence Pricing: Retail pharmacy chains (CVS, Walgreens) and commercial health plans face tight margins on seasonal flu vaccines. Moderna must price mFLUSIVA competitively against established high-dose flu shots ($65–$85 per dose) to secure preferred formulary positioning without triggering restrictive prior authorization edits.

---

Frequently Asked Questions (FAQ)

What is mFLUSIVA (mRNA-1010) and when is its FDA PDUFA date?

mFLUSIVA (mRNA-1010) is Moderna's investigational trivalent seasonal influenza mRNA vaccine. Following a unanimous 9-0 favorable vote by the FDA VRBPAC advisory committee on June 18, 2026, the FDA set a PDUFA goal date of August 5, 2026 for its Biologics License Application (BLA).

How many mRNA vaccine trials are currently in clinical development globally?

Analysis of ClinicalTrials.gov registry data reveals 459 total clinical trials evaluating mRNA vaccines. Of these, 277 studies (60.3%) target COVID-19, while ~182 studies target non-COVID indications, including seasonal flu (35), RSV (15), HSV (14), CMV (8), HIV (6), and therapeutic cancer vaccines (50).

How did the COVID-19 pandemic impact annual mRNA trial initiations?

New mRNA trial starts peaked at 129 in 2021 before declining sharply to 91 in 2022, 72 in 2023, and a trough of 38 in 2024. Initiations experienced a second-wave recovery to 45 in 2025 and 28 year-to-date in 2026, driven primarily by non-COVID respiratory and cancer vaccine programs.

Which biopharma companies lead the global mRNA vaccine pipeline?

ModernaTX leads the global industry with 68 clinical trials (26.4% of all commercial studies), followed by BioNTech (31 trials), Sanofi (16 trials), GlaxoSmithKline (13 trials), AIM Vaccine (13 trials), and Pfizer (10 trials).

What is the difference between conventional mRNA and self-amplifying mRNA (sa-mRNA)?

Conventional mRNA encodes only the target antigen. Self-amplifying mRNA (sa-mRNA) also encodes an alphavirus replicase enzyme that multiplies the mRNA template inside host cells. This enables sa-mRNA vaccines (such as Arcturus/CSL's Kostaive) to achieve potent immune responses at one-tenth the RNA dose, reducing reactogenicity and manufacturing costs.

---

Sources

1. ModernaTX, Inc. Press Release: FDA Advisory Committee Votes Unanimously (9-0) in Favor of Benefit-Risk Profile of Moderna's Seasonal Influenza Vaccine (mFLUSIVA / mRNA-1010). Published June 18, 2026. Available via BioSpace and Moderna Investor Relations.
2. FDA VRBPAC Committee / FDA.gov: Vaccines and Related Biological Products Advisory Committee Meeting Materials & mFLUSIVA BLA Review. US Food and Drug Administration. Available via FDA.gov.
3. BioPharm International: FDA Advisory Panel Votes 9-0 in Favor of Moderna's mRNA Flu Vaccine, Setting Stage for August Decision. Published June 19, 2026.
4. ClinicalTrials.gov Registry: Global mRNA Prophylactic & Therapeutic Vaccine Clinical Trial Cohort Analysis. Dataset snapshot July 25, 2026 (595,630 total studies scanned). Available via ClinicalTrials.gov.
5. Pharmaceutical Technology & PubMed: Moderna's mRNA Flu Vaccine Passes FDA AdCom, Regulatory Review Underway. Published June 2026. Available via PubMed.